RPg Family Wealth Advisory’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

RPg Family Wealth Advisory’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,900	Closed	-$34.2K	–	118
2022 Q1	$34.2K	Hold	1,900	–	–	0.01%	177
2021 Q4	$45.2K	Hold	1,900	–	–	0.02%	169
2021 Q3	$57.7K	Hold	1,900	–	–	0.02%	160
2021 Q2	$60.6K	Buy	+1,900	New	+$57.3K	0.02%	163
2020 Q4	$60.8K	Sell	1,900 -700	-27%	-$21K	0.03%	154
2020 Q3	$71.4K	Sell	2,600 -450	-15%	-$12K	0.04%	147
2020 Q2	$82.6K	Sell	3,050 -1,150	-27%	-$28.2K	0.05%	142
2020 Q1	$82K	Buy	4,200 +1,250	+42%	+$26.9K	0.06%	114
2019 Q4	$69.1K	Sell	2,950 -1,341	-31%	-$28.4K	0.04%	140
2019 Q3	$80.5K	Sell	4,291 -880	-17%	-$17.9K	0.05%	126
2019 Q2	$109K	Hold	5,171	–	–	0.06%	112
2019 Q1	$109K	Buy	5,171 +1,250	+32%	+$26.2K	0.06%	113
2018 Q4	$74K	Sell	3,921 -1,100	-22%	-$22.9K	0.07%	87
2018 Q3	$125K	Buy	5,021 +2,280	+83%	+$56K	0.09%	73
2018 Q2	$66.2K	Buy	+2,741	New	+$73.9K	0.05%	102

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

RPg Family Wealth Advisory's CNCR Position: Q2 2022 in Review

RPg Family Wealth Advisory sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2022, closing a stake of 1,900 shares — an estimated $34.2K sold.

RPg Family Wealth Advisory first reported a position in CNCR in Q2 2018 and held it in 15 quarters. The position peaked at $125K in Q3 2018. 20 funds tracked by Wall St. Rank hold CNCR as of Q2 2022.

RPg Family Wealth Advisory reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2022 after selling out during the quarter.
RPg Family Wealth Advisory sold 1,900 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2022, an estimated $34.2K.
RPg Family Wealth Advisory first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2018 and held it in 15 quarters.
RPg Family Wealth Advisory's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $125K in Q3 2018.
20 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2022.

Based on RPg Family Wealth Advisory's 13F filing for Q2 2022, filed 12 Aug 2022.